HDAC6 exacerbates osteoarthritis by promoting macrophage inflammation-mediated chondrocyte degeneration
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116399 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Shimin Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Chondrocytes, Osteoarthritis, Macrophages. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Guangzhou Science and Technology Program Key Projects, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis (OA) is a degenerative joint disorder characterized by cartilage degradation and synovial inflammation, with its pathogenesis involving intricate interactions between cellular metabolic processes and inflammatory pathways. In this study, we established OA models in both wild-type and histone deacetylase 6 (HDAC6) knockout mice via anterior cruciate ligament transection (ACLT) to investigate the role of HDAC6 in OA progression. Histological and immunohistochemical analyses revealed that the absence of HDAC6 significantly mitigated ACLT-induced cartilage damage and synovitis in mice, while also restoring imbalances in cartilage metabolic markers. In vitro experiments demonstrated that, upon stimulation with inflammatory factors IL-1β or TNF-α, neither HDAC6 overexpression nor knockdown significantly altered the metabolic processes of chondrocytes, suggesting that HDAC6 may not directly regulate chondrocyte metabolism in an inflammatory context. However, conditioned medium from macrophages overexpressing HDAC6 promoted catabolic processes in chondrocytes and inhibited anabolic processes, whereas the knockdown of HDAC6 reversed this effect. These findings imply that HDAC6 contributes to the progression of OA by amplifying macrophage-mediated synovial inflammation, thereby indirectly disrupting the metabolic homeostasis of chondrocytes. In conclusion, these results suggest that targeting HDAC6 may provide a novel strategy for alleviating OA pathology by modulating macrophage-chondrocyte interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
- Department of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Electronic address: jinfujun@gdut.edu.cn.
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Electronic address: luyj@gdut.edu.cn.
- Department of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: lg2781@smu.edu.cn.
Förderung
- Guangzhou Science and Technology Program Key Projects
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Fu, L., Qiu, W., Ouyang, J., Song, D., Song, Z., Zhu, Y., Yan, Z., Jin, F., Lu, Y. J., & Liu, G. (2026). HDAC6 exacerbates osteoarthritis by promoting macrophage inflammation-mediated chondrocyte degeneration. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116399
Vancouver
Wang S, Fu L, Qiu W, Ouyang J, Song D, Song Z, et al. HDAC6 exacerbates osteoarthritis by promoting macrophage inflammation-mediated chondrocyte degeneration. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116399
BibTeX
@article{Wang2026,
author = {Wang, Shimin and Fu, Liping and Qiu, Wenquan and Ouyang, Junyu and Song, Delong and Song, Zilong and Zhu, Yexuan and Yan, Zheng and Jin, Fujun and Lu, Yu-Jing and Liu, Gang},
title = {HDAC6 exacerbates osteoarthritis by promoting macrophage inflammation-mediated chondrocyte degeneration},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116399}
}
EUVIMED